α -酮类似物能减缓非透析依赖性慢性肾病的疾病进展吗?

Journal of Biology and Life Science Pub Date : 2023-10-05 DOI:10.37185/lns.1.1.407

Bilal Saeed, Khayam ., Zabihullah Afridi, Muhammad Sana Ullah

{"title":"α -酮类似物能减缓非透析依赖性慢性肾病的疾病进展吗?","authors":"Bilal Saeed, Khayam ., Zabihullah Afridi, Muhammad Sana Ullah","doi":"10.37185/lns.1.1.407","DOIUrl":null,"url":null,"abstract":"Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients.Study Design: Quasi-experimental study.Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023.Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered significant.Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A (low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was 1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000). Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis dependent but still controversial. How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407","PeriodicalId":15254,"journal":{"name":"Journal of Biology and Life Science","volume":"302 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?\",\"authors\":\"Bilal Saeed, Khayam ., Zabihullah Afridi, Muhammad Sana Ullah\",\"doi\":\"10.37185/lns.1.1.407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients.Study Design: Quasi-experimental study.Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023.Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered significant.Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A (low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was 1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000). Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis dependent but still controversial. How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407\",\"PeriodicalId\":15254,\"journal\":{\"name\":\"Journal of Biology and Life Science\",\"volume\":\"302 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biology and Life Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37185/lns.1.1.407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biology and Life Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37185/lns.1.1.407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的:观察酮类药物延缓非透析依赖性CKD患者病情进展的效果。研究设计:准实验研究。研究地点和时间:研究于2022年8月至2023年2月28日在巴基斯坦白沙瓦联合军事医院(CMH)肾脏病科进行。方法:采用非概率连续抽样技术收集290例肾脏疾病改善总体结局(KDIGO) 3期和4期CKD患者的数据。研究对象分为A组(低蛋白饮食)和B组(生酮饮食)。A组在低蛋白饮食的基础上进行标准慢性疾病治疗，B组为酮饮食组，在低蛋白饮食的基础上进行酮类似物治疗，并进行标准慢性肾脏疾病治疗。计算并比较两组的基线和6个月eGFR。采用SPSS 23.00版本进行数据分析。P值≤0.05为差异有统计学意义。结果:入选患者286例，年龄51.84±18.127岁。其中男性188例(65.73%)，女性98例(34.26%)。A组142例(50.34%)，B组144例(50.34%)。A、B组CKD病程分别为6.45±2.55年和6.49±1.75年。A组(低蛋白饮食)eGFR在基线和6个月后的平均差异为3.64±1.09mL/ min/ 1.73m2, B组为1.48±0.41 mL/ min/ 1.73m2 (p值<0.000)。结论:酮类似物是一种新兴的治疗方法，可减缓非透析依赖性CKD患者的疾病进展。虽然它被一些临床医生推荐用于CKD 3期和4期非透析依赖患者，但仍存在争议。Saeed B, Khayam, Afridi Z, Ullah MS. α -酮类似物是否减缓非透析依赖性慢性肾病的疾病进展?生命与科学。2023;4(4): 427 - 431。doi: http://doi.org/10.37185/LnS.1.1.407

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?

Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients.Study Design: Quasi-experimental study.Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023.Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered significant.Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A (low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was 1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000). Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis dependent but still controversial. How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Biology and Life Science

自引率

0.00%

发文量